mal-phe-c4-val-cit-pab

Mal-Phe-C4-Val-Cit-PAB is a cleavable antibody-drug conjugate (ADC) linker with a Maleimide functional group used in ADC synthesis.

The chemical compound Mal-Phe-C4-Val-Cit-PAB-DMEA is a cleavable antibody-drug conjugate (ADC) linker that incorporates a Maleimide group. It is commonly employed in the synthesis of ADCs.

Boc-Val-Cit-OH is a cleavable ADC linker utilized in the synthesis of antibody-drug conjugates (ADCs).

Mal-PEG1-Val-Cit-OH is a cleavable one-unit polyethylene glycol (PEG) linker used in the synthesis of antibody-drug conjugates (ADCs) [1].

Mc-Val-Ala-PAB, an effective linker, is utilized in antibody-drug-conjugate (ADC).

Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC. Val-Cit-PAB-MMAE contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin inhibitor MMAE . MMAE a potent mitotic inhibitor by inhibiting tubulin polymerization[1].

MC-Val-Cit-PAB is a cathepsin cleavable ADC linker that is used for making antibody-drug conjugate. FDA approved drugs such as brentuximab vedotin use this linker.

Fmoc-Val-Cit-PAB-MMAE is consisted of the ADCs linker (Fmoc-Val-Cit-PAB) and potent tubulin inhibitor (MMAE). Fmoc-Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC.

Phe-Lys(Trt)-PAB is a cathepsin-cleavable linker used in the development of antibody-drug conjugates (ADCs), serving as a crucial component for releasing therapeutic agents within targeted cells.

MC-Val-Ala-PAB-PNP is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Fmoc-Val-Cit-PAB is a linker used for antibody-drug-conjugation (ADC).

MC-Val-Cit-PABC-PNP, also known as Mc-Val-Cit-PABC-PNP, is a cathepsin cleavable ADC peptide linker. For example, FDA approved drug, brentuximab vedotin, adopts this linker. Protein- and peptide-drug conjugates hold a promising stance in the delivery of therapeutic agents by providing distinct advantage of improving therapeutic potential of drugs. Use of specialized linkers makes them unique in their in vivo therapeutic application by providing target tissue-specific release of drug.

Boc-Val-Cit-PAB is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Mc-Val-Cit-PAB-Cl, a cleavable ADC linker, is utilized in the conjugation of MMAE and antibodies to produce compounds such as antibody-MC-vc-MMAE (e.g., anti-CD22-MC-VC-PABC-MMAE), which demonstrate cytotoxicity with IC50s of 3.3 and 0.95 nM against BJAB and WSU cell lines, respectively.

Val-cit-PAB-OH is an ADC linker that is cleavable.

Val-Cit is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Mal-Phe-C4-VC-PAB-MMAE is a chemical compound formed by conjugating monomethyl auristatin E (MMAE), a potent tubulin inhibitor used as a toxin payload in antibody-drug conjugates, with a Mal-Phe-C4-VC-PAB linker.

Endo-BCN-PEG4-Val-Cit-PAB-MMAE is a cleavable four-unit polyethylene glycol (PEG) linker, specifically designed for the synthesis of antibody-drug conjugates (ADCs)[1].

Mal-VC-PAB-ABAEP-Azonafide, an ADC (antibody-drug conjugate) linker-drug conjugate, demonstrates potent antitumor activity. It incorporates Azonafide, a cytotoxin, connected through the ADC linker Mal-VC-PAB[1].

TCO-PEG1-Val-Cit-PABC-OH, a cleavable 1-unit PEG ADC linker, is employed in the synthesis of antibody-drug conjugates (ADCs)[1].

MC-Val-Cit-PAB-rifabutin is a drug-linker conjugate for antibody-drug conjugates (ADC), featuring the potent antitumor agent rifabutin (a DNA-dependent RNA polymerase inhibitor) connected via the MC-Val-Cit-PAB ADC linker, which endows it with significant antitumor activity.

Mal-PEG4-Val-Cit-PAB-PNP is a cleavable, 4-unit polyethylene glycol (PEG) linker used in the synthesis of antibody-drug conjugates (ADCs)[1].

Mal-PEG4-Val-Cit-PAB-OH, a cleavable 4-unit PEG ADC linker, is employed in the synthesis of antibody-drug conjugates (ADCs)[1].

Acid-propionylamino-Val-Cit-OH is a cleavable linker commonly used in the synthesis of antibody-drug conjugates (ADCs) [1].

Azido-PEG1-Val-Cit-OH is a cleavable, one-unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs) [1].

Boc-Phe-(Alloc)Lys-PAB-PNP serves as a cleavable linker in the synthesis of antibody-drug conjugates (ADCs).

Amino-PEG4-Val-Cit-PAB-MMAE is a cleavable tetraethylene glycol (4 unit PEG) antibody-drug conjugate (ADC) linker used in the synthesis of ADCs[1].

Mal-VC-PAB-DM1, a drug-linker conjugate for antibody-drug conjugates (ADCs), exhibits potent antitumor activity. It incorporates DM1, a potent microtubule-disrupting agent, connected through the ADC linker Mal-VC-PAB [1].

MC-Sq-Cit-PAB-Dolastatin10 is a potent antitumor drug-linker conjugate for Antibody-Drug Conjugates (ADC), incorporating Dolastatin10 (a tubulin polymerization inhibitor) connected via the MC-Sq-Cit-PAB ADC linker.

OPSS-Val-Cit-PAB-PNP, a cleavable linker used in ADC (antibody-drug conjugates) synthesis [1].

Boc-Val-Ala-PAB-PNP is an ADC linker used in the synthesis of antibody-drug conjugates (ADCs)[1]. This cleavable compound efficiently facilitates drug-attachment to antibodies, allowing for targeted therapeutic delivery and release, thus playing a crucial role in ADC development.

MAL-di-EG-Val-Cit-PAB-MMAF is a chemical compound consisting of the linker (MAL-di-EG-Val-Cit-PAB) and the potent tubulin polymerization inhibitor (MMAF, Monomethyl auristatin F) [1].

Mal-amido-PEG2-Val-Cit-PAB-PNP is a cleavable, 2-unit polyethylene glycol (PEG) based ADC linker used in the construction of antibody-drug conjugates (ADCs) [1].

MC-Val-Cit-PAB-dimethylDNA31 is a drug-linker conjugate employed in antibody-drug conjugates (ADCs) that exhibits robust antitumor efficacy. This conjugate utilizes the ADC linker, MC-Val-Cit-PAB, to connect with the potent antitumor agent dimethylDNA31, which also demonstrates significant bactericidal activity against both persister and stationary-phase [Staphylococcus aureus].

OPSS-Val-Cit-PAB-OH is an ADC linker used for the synthesis of antibody-drug conjugates (ADCs) [1].

Mal-amido-PEG8-val-gly-PAB-OH, an eight-unit PEG cleavable linker, is frequently employed in the synthesis of antibody-drug conjugates (ADCs)[1].

Mal-Phe-C4-VC-PAB-DMEA-PNU-159682 is a drug-linker conjugate utilized in antibody-drug conjugate (ADC) therapy. It comprises the ADC linker Mal-Phe-C4-VC-PAB and the potent ADC cytotoxin DMEA-PNU-159682, which encompasses metabolites of nemorubicin (MMDX) derived from liver microsomes, as well as the ADC cytotoxin PNU-159682 [1].

Mal-PEG4-VC-PAB-DMEA, a cleavable ADC linker incorporating a Maleimide moiety, is employed in the synthesis of antibody-drug conjugates (ADCs)[1].

DBCO-(PEG2-Val-Cit-PAB)2 is a dual-cleavable linker used in antibody-drug conjugates (ADCs).

Mal-PEG8-Val-Cit-PAB-MMAE is a cleavable 8-unit PEG ADC linker utilized in the synthesis of antibody-drug conjugates (ADCs)[1].

DBCO-Val-Cit-PABC-PNP is a cleavable linker used in the synthesis of antibody-drug conjugates (ADC) [1].

SuO-Val-Cit-PAB-MMAE is an ADC (antibody-drug conjugate) linker composed of the anti-mitotic monomethyl auristatin E (MMAE, a tubulin inhibitor) linked via the SuO-Val-Cit-PAB peptide.

Fmoc-Phe-Lys(Trt)-PAB-PNP is a cleavable linker designed specifically for antibody-drug conjugate (ADC) synthesis.

MC-Val-Cit-PAB-Auristatin E is an antibody-drug conjugate (ADC) linker compound with Auristatin E, a potent cytotoxic tubulin modifier, attached via the MC-Val-Cit-PAB linker, demonstrating significant antitumor activity.

Fmoc-Phe-Lys(Boc)-PAB-PNP is a cleavable antibody-drug conjugate (ADC) linker utilized in ADC synthesis.

DBCO-Val-Cit-PABC-OH, a cleavable linker, is used in the synthesis of antibody-drug conjugates (ADCs) [1].

Mal-PEG2-Val-Cit-amido-PAB-OH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Mal-PEG4-Val-Cit-PAB, a cleavable ADC linker incorporating a Maleimide moiety, finds application in the construction of antibody-drug conjugates (ADCs)[1].

Mal-amido-PEG2-Val-Cit-PAB-OH is a bi-functional polyethylene glycol (PEG) linker, composed of two PEG units, that is cleavable and specifically designed for the synthesis of antibody-drug conjugates (ADCs)[1].

Mal-PEG4-VC-PAB-DMEA-PNU-159682 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) therapy. It combines the ADC linker, Mal-PEG4-VC-PAB, with the potent ADC cytotoxin, DMEA-PNU-159682. The cytotoxin, DMEA-PNU-159682, is derived from metabolites of nemorubicin (MMDX) found in liver microsomes, as well as the ADC cytotoxin PNU-159682 [1].